- Home
- AESI vs ETNB Comparison
AESI vs ETNB Comparison
Compare AESI & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AESI
- ETNB
- Stock Information
- Founded
- AESI 2017
- ETNB 2018
- Country
- AESI United States
- ETNB United States
- Employees
- AESI N/A
- ETNB N/A
- Industry
- AESI Metal Fabrications
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- AESI Industrials
- ETNB Health Care
- Exchange
- AESI Nasdaq
- ETNB Nasdaq
- Market Cap
- AESI 1.7B
- ETNB 1.5B
- IPO Year
- AESI 2023
- ETNB 2019
- Fundamental
- Price
- AESI $14.40
- ETNB $10.08
- Analyst Decision
- AESI Buy
- ETNB Strong Buy
- Analyst Count
- AESI 9
- ETNB 8
- Target Price
- AESI $20.17
- ETNB $26.43
- AVG Volume (30 Days)
- AESI 1.6M
- ETNB 2.2M
- Earning Date
- AESI 08-04-2025
- ETNB 08-04-2025
- Dividend Yield
- AESI 6.69%
- ETNB N/A
- EPS Growth
- AESI N/A
- ETNB N/A
- EPS
- AESI 0.30
- ETNB N/A
- Revenue
- AESI $1,160,881,000.00
- ETNB N/A
- Revenue This Year
- AESI $13.36
- ETNB N/A
- Revenue Next Year
- AESI $4.93
- ETNB N/A
- P/E Ratio
- AESI $47.87
- ETNB N/A
- Revenue Growth
- AESI 77.72
- ETNB N/A
- 52 Week Low
- AESI $11.76
- ETNB $4.16
- 52 Week High
- AESI $26.86
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- AESI 59.31
- ETNB 57.88
- Support Level
- AESI $14.25
- ETNB $9.66
- Resistance Level
- AESI $14.93
- ETNB $10.58
- Average True Range (ATR)
- AESI 0.53
- ETNB 0.55
- MACD
- AESI 0.20
- ETNB -0.09
- Stochastic Oscillator
- AESI 81.99
- ETNB 58.39
About AESI Atlas Energy Solutions Inc.
Atlas Energy Solutions Inc is a provider of proppant and logistics services to the oil and natural gas industry within the Permian Basin of West Texas and New Mexico, the most active oil and natural gas basin in North America. Proppant is necessary to facilitate the recovery of hydrocarbons from oil and natural gas wells. One hundred percent of its sand reserves are located in Winkler and Ward Counties, Texas, within the Permian Basin, and its operations consist of proppant production and processing facilities, including two facilities near Kermit, Texas, and a third facility near Monahans, Texas.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).